Blood Res 2017; 52(3):
Published online September 25, 2017
https://doi.org/10.5045/br.2017.52.3.159
© The Korean Society of Hematology
1Department of Hematology, Navy General Hospital of PLA, Beijing, China.
2Department of Hematology, Iuliu Hatieganu University, Cluj Napoca, Romania.
3Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.
4Department of Neurosurgery, Emergency University Hospital, Cluj Napoca, Romania.
5Department of Hematology, Navy General Hospital of PLA, Beijing, China.
Correspondence to : Liren Qian, M.D. Department of Hematology, Navy General Hospital, Fucheng Road, Beijing 100048, China. qlr2007@126.com
Primary central nervous system lymphoma (PCNSL) is a type of highly invasive non-Hodgkin lymphoma. With a growing number of organ transplantation and immunosuppressant therapy, the incidence of PCNSL has been growing rapidly in recent years, which is attributed to the increased incidence of HIV/AIDS, a prominent risk factor for developing PCNSL. The rising rate of PCNSL incidence is the highest among the intracranial tumors. In the past 20 years, dozens of clinical trials related to PCNSL have been registered, but adequate therapeutics are still challenging. Currently, the chemotherapy regimens based on high-dose methotrexate and whole-brain radiotherapy are the two main therapeutic options; however, the toxicity associated with those is the main problem that challenges medical researchers. Novel agents and therapeutic strategies have been developed in recent years. In the current review, we describe advances in the treatment of PCNSL and discuss novel therapeutic approaches currently in development, such as the use of rituximab, disruption of the blood-brain barrier, and state-of-the-art radiotherapy.
Keywords Primary central nervous system lymphoma, Methotrexate, Whole-brain radiotherapy, Rituximab
Blood Res 2017; 52(3): 159-166
Published online September 25, 2017 https://doi.org/10.5045/br.2017.52.3.159
Copyright © The Korean Society of Hematology.
Liren Qian1*, Ciprian Tomuleasa2,3*, Ioan-Alexandru Florian4, Jianliang Shen5, Ioan-Stefan Florian4, Mihnea Zdrenghea2,3, and Delia Dima3
1Department of Hematology, Navy General Hospital of PLA, Beijing, China.
2Department of Hematology, Iuliu Hatieganu University, Cluj Napoca, Romania.
3Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.
4Department of Neurosurgery, Emergency University Hospital, Cluj Napoca, Romania.
5Department of Hematology, Navy General Hospital of PLA, Beijing, China.
Correspondence to:Liren Qian, M.D. Department of Hematology, Navy General Hospital, Fucheng Road, Beijing 100048, China. qlr2007@126.com
Primary central nervous system lymphoma (PCNSL) is a type of highly invasive non-Hodgkin lymphoma. With a growing number of organ transplantation and immunosuppressant therapy, the incidence of PCNSL has been growing rapidly in recent years, which is attributed to the increased incidence of HIV/AIDS, a prominent risk factor for developing PCNSL. The rising rate of PCNSL incidence is the highest among the intracranial tumors. In the past 20 years, dozens of clinical trials related to PCNSL have been registered, but adequate therapeutics are still challenging. Currently, the chemotherapy regimens based on high-dose methotrexate and whole-brain radiotherapy are the two main therapeutic options; however, the toxicity associated with those is the main problem that challenges medical researchers. Novel agents and therapeutic strategies have been developed in recent years. In the current review, we describe advances in the treatment of PCNSL and discuss novel therapeutic approaches currently in development, such as the use of rituximab, disruption of the blood-brain barrier, and state-of-the-art radiotherapy.
Keywords: Primary central nervous system lymphoma, Methotrexate, Whole-brain radiotherapy, Rituximab
Yoon Seok Choi
Blood Res 2020; 55(S1): S58-S62Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50